Active Ingredient(s):Satralizumab FDA Approved: * August 14, 2020 Pharm Company: *GENENTECH Category:Immunosuppressive
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach...
* May have multiple approval dates, manufacturers, or labelers.